Journals / Turkish Journal of Gastroenterology / 2015 / Cilt: 26 - Sayı: 1

The relationship between serum adiponectin and resistin levels, insulin resistance and colorectal adenomas

Pages
20–24
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Our data indicate that obesity and insulin resistance may contribute to the development of colorectal adenoma and that serum adiponectin levels and insulin resistance may not have a substantial predictive value for colorectal adenoma

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: The relationship between adipocytokines and the development of colorectal cancer is welldocumented.
📊
Key Findings & Data:Materials and Methods: This is a cross-sectional case-control study conducted in 32 patients with colorectal adenoma and 30 control subjects.
💡
Conclusion & Impact:Conclusion: Our data indicate that obesity and insulin resistance may contribute to the development of colorectal adenoma and that serum adiponectin levels and insulin resistance may not have a substantial predictive value for colorectal adenoma
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background/Aims: The relationship between adipocytokines and the development of colorectal cancer is welldocumented. Our aim was to assess the relationship among serum adiponectin and resistin levels, insulin resistance, and colorectal adenoma to evaluate whether these parameters can be used as biomarkers to predict the development of colorectal adenoma. Materials and Methods: This is a cross-sectional case-control study conducted in 32 patients with colorectal adenoma and 30 control subjects. Serum adiponectin and resistin levels, body mass index values, waist and hip circumferences and Homeostasis Model Assessment scores were measured. Results: Resistin levels were slightly higher and adiponectin was slightly lower in patients with colorectal adenoma compared with controls; however, the differences in both parameters failed to reach statistical significance. The body mass index values and waist circumference of the patient group were significantly higher than controls (p=0.003 and p=0.002, respectively). Fasting serum insulin levels and Homeostasis Model Assessment scores of patients with colorectal adenoma were significantly higher than those of controls (p=0.02 and p=0.02, respectively). There was no relation between the number of colorectal adenomas and serum adiponectin or resistin levels. Conclusion: Our data indicate that obesity and insulin resistance may contribute to the development of colorectal adenoma and that serum adiponectin levels and insulin resistance may not have a substantial predictive value for colorectal adenoma

🔖

Cite This Article

DEMİR, N., AHISHALI, E., DOLAPÇIOĞLU, C., ERCAN, Ş., ORÇUN, A. K., DABAK, R., YÜCEL, N., SARGIN, M., UYGUR, O. B. (2015). The relationship between serum adiponectin and resistin levels, insulin resistance and colorectal adenomas. Turkish Journal of Gastroenterology, Cilt: 26 - Sayı: 1, 20–24. https://ajindex.com/articles/410246

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Wiecek A, Kokot F, Chudek J, Adarnczak M. The adipose tissue a novel endocrine organ of interest to the nephrologist. Nefrol Dial Transplant 2002
  2. [CrossRef] Shuldiner AR, Yang R, Gong DW. Resistin, obesity and insulin resistance-the emerging role of the adipocyte as an endocrine organ. N Engl J Med 2001
  3. [CrossRef] John BJ, Irukulla S, Abulafi AM, Kumar D, Mendall MA. Systematic review: adipose tissue, obesity and gastrointestinal diseases. Aliment Pharmacol Ther 2006
  4. [CrossRef] Iannucci CV, Capoccia D, Calabria M, Leonetti F. Metabolic syndrome and adipose tissue: new clinical aspects and therapeutic targets. Curr Pharm Des 2007
  5. [CrossRef] Stumvoll M, Häring H. Insulin resistance and insulin sensitizers. Horm Res 2001
  6. [CrossRef] Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001
  7. [CrossRef] Rea R, Donnelly R. Resistin: an adipocyte-derived hormone. Has it a role in diabetes and obesity? Diabetes Obes Metab 2004
  8. [CrossRef] Wasim H, Al-Daghri NM, Chetty R, McTernan PG, Barnett AH, Kumar S. Relationship of serum adiponectin and resistin to glucose intolerance and fat topography in South-Asians. Cardiovasc Diabetol 2006
  9. [CrossRef] Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin the classical, resistin-the controversical, adiponectin-the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005
  10. [CrossRef] Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004
  11. [CrossRef] Nedvídková J, Smitka K, Kopský V, Hainer V. Adiponectin, an adipocyte-derived protein. Physiol Res 2005
  12. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005
  13. [CrossRef] Hug C, Lodish HF. The role of the adipocyte hormone adiponectin in cardiovascular disease. Curr Opin Pharmacol 2005
  14. [CrossRef] Fantuzzi G. Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol 2008
  15. [CrossRef] Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002
  16. [CrossRef] Spranger J, Kroke A, Möhlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003
  17. [CrossRef] Doyle SL, Donohoe CL, Lysaght J, Reynolds JV. Visceral obesity, metabolic synd